Idarubicin Hydrochloride Injection Recalled Due to Sterility Concerns
Teva Pharmaceuticals USA is recalling Idarubicin Hydrochloride Injection 20 mg/20 mL vials nationwide due to lack of assurance of sterility. The recall affects 2,091 vials distributed across the United States and Puerto Rico.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall involving a sterility defect in an injectable chemotherapy drug. Lack of sterility assurance in injectable medications poses risk of serious infection and potentially requires hospitalization, meeting the Severe criteria for Class II recalls with significant potential for harm.
Plain-English summary
Teva Pharmaceuticals USA is recalling Idarubicin Hydrochloride Injection 20 mg/20 mL (single-dose vials) due to lack of assurance of sterility. The affected product is NDC 0703-4156-11, Lot #31328668B with an expiration date of April 2023.
The recall affects 2,091 vials that were distributed nationwide, including Puerto Rico. Idarubicin hydrochloride is a chemotherapy medication used to treat cancer patients. Without assurance of sterility, there is a potential risk of serious infection if contaminated product is administered.
Patients currently using this medication should contact their healthcare provider immediately. Healthcare providers should quarantine remaining product from the affected lot and not dispense it to patients. Any product from Lot #31328668B should be returned to Teva Pharmaceuticals USA or disposed of according to applicable regulations.
The recalled product
- Product
- Idarubicin Hydrochloride Injection 20 mg/20 mL, 20 mL single-dose vial, Rx only, Teva Pharmaceuticals USA, Inc. North Wales, PA 19454, NDC 0703-4156-11
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Injectable Chemotherapy
- Hazard
- sterility-assurance
- infection-risk
- injectable-contamination
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: 31328668B
- exp. date 04/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27